Trial
NCT00538681
Study for Participants With Advanced, Not Amenable to Surgery, or Metastatic Lung Cancer Comparing Treatment With Pemetrexed + Cisplatin + Enzastaurin Versus Pemetrexed + Cisplatin + Placebo
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Eli Lilly and Company
Collaborators
—
Condition
Lung Cancer
Intervention
enzastaurin
Why stopped
Terminated due to lack of efficacy demonstrated in relevant participant population in other clinical trials.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-11-05